STEPHEN PAPPAS to Lypressin
This is a "connection" page, showing publications STEPHEN PAPPAS has written about Lypressin.
Connection Strength
0.769
-
Predictors of Response to Terlipressin in Hepatorenal Syndrome. Clin Gastroenterol Hepatol. 2018 07; 16(7):1174.
Score: 0.151
-
Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies. Aliment Pharmacol Ther. 2017 Jun; 45(11):1390-1402.
Score: 0.141
-
Terlipressin Improves Renal Function and Reverses Hepatorenal?Syndrome in Patients With Systemic Inflammatory?Response?Syndrome. Clin Gastroenterol Hepatol. 2017 02; 15(2):266-272.e1.
Score: 0.134
-
Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1. Gastroenterology. 2016 Jun; 150(7):1579-1589.e2.
Score: 0.130
-
Decreased need for RRT in liver transplant recipients after pretransplant treatment of hepatorenal syndrome-type 1 with terlipressin. Liver Transpl. 2024 04 01; 30(4):347-355.
Score: 0.055
-
The Effect of Terlipressin on Renal Replacement Therapy in Patients with Hepatorenal Syndrome. Kidney360. 2023 08 01; 4(8):1030-1038.
Score: 0.054
-
Terlipressin Treatment Is Associated With Reversal of Hepatorenal Syndrome in Patients With Alcoholic Hepatitis. Clin Gastroenterol Hepatol. 2023 12; 21(13):3455-3457.e3.
Score: 0.053
-
Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute-on-chronic liver failure. Aliment Pharmacol Ther. 2022 10; 56(8):1284-1293.
Score: 0.051